ADTX ADITXT INC US FDA Inspections 8-K Filing 2024 - Therapeutic Progress Aditxt, Inc. announced that its subsidiary, Adimune, has successfully completed preclinical efficacy and safety studies for its immune modulation therapeutic platform, with presentation materials available on Adimune's website.Get access to all SEC 8-K filings of the ADITXT INC